| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
A case of autosomal recessive hypercholesterolemia caused by a new variant in the LDL receptor adaptor protein 1 gene
|
Vaverkova, Helena
|
|
2019
|
13 |
3 |
p. 405-410
|
artikel
|
| 2 |
Acute Effects of Curcuminoids, EPA (Omega - 3), Astaxanthin and GLA On Cardiovascular Health
|
Birudaraju, Divya
|
|
2019
|
13 |
3 |
p. e48-e49
|
artikel
|
| 3 |
Alirocumab Reduces Total Nonfatal Cardiovascular and Fatal Events in the ODYSSEY OUTCOMES Trial†
|
Pordy, Robert
|
|
2019
|
13 |
3 |
p. e54-e55
|
artikel
|
| 4 |
A lost decade: No Meaningful Changes in LDL Cholesterol in the United States, 2008-2017: Insights from a National Reference Laboratory
|
Kaufman, Harvey
|
|
2019
|
13 |
3 |
p. e12-e13
|
artikel
|
| 5 |
A novel mutation of APOB in two siblings with hypercholesterolemia
|
Sprunger II, Abigail
|
|
2019
|
13 |
3 |
p. e19
|
artikel
|
| 6 |
An updated cost-effectiveness analysis of evolocumab therapy for reducing cardiovascular events in very high-risk patients with atherosclerotic cardiovascular disease according to the 2018 ACC/AHA guideline
|
Fonarow, Gregg C.
|
|
2019
|
13 |
3 |
p. e31
|
artikel
|
| 7 |
A Randomized Study of Evolocumab in Patients With Type 2 Diabetes and Dyslipidemia on Background Statin: Primary Results of the BERSON Clinical Trial
|
Lorenzatti, Alberto J.
|
|
2019
|
13 |
3 |
p. e5-e6
|
artikel
|
| 8 |
A 3-SNP gene risk score and a metabolic risk score both predict hypertriglyceridemia and cardiovascular disease risk
|
Verbeek, Rutger
|
|
2019
|
13 |
3 |
p. 492-501
|
artikel
|
| 9 |
Association between Lipids and Coronary Atherosclerotic Plaque Characteristics
|
Cherukuri, Lavanya
|
|
2019
|
13 |
3 |
p. e28-e29
|
artikel
|
| 10 |
Atypical familial dysbetalipoproteinemia associated with high polygenic cholesterol and triglyceride scores treated with ezetimibe and evolocumab
|
Morise, Anthony P.
|
|
2019
|
13 |
3 |
p. 411-414
|
artikel
|
| 11 |
Awarness of Risk factors decrease CVD*
|
Jiva, Erum Sohail
|
|
2019
|
13 |
3 |
p. e49-e51
|
artikel
|
| 12 |
Case Presentation: A family history of early myocardial infarction in a family with elevated lipoprotein(a)
|
Ayers, Michael Parker
|
|
2019
|
13 |
3 |
p. e36
|
artikel
|
| 13 |
Case report: The efficacy and safety of lomitapide in a homozygous familial hypercholesterolemic child
|
Chacra, Ana Paula M.
|
|
2019
|
13 |
3 |
p. 397-401
|
artikel
|
| 14 |
Changing Between PCSK9 Inhibitor Medications
|
Trippi, James
|
|
2019
|
13 |
3 |
p. e8
|
artikel
|
| 15 |
Characterization of Familial Hypercholesterolemia Management at an Academic Medical Center*
|
Hess, Danielle
|
|
2019
|
13 |
3 |
p. e39-e40
|
artikel
|
| 16 |
Clinical Management of Elevated Lipoprotein(a) in A Large Cohort of Familial Hypercholesterolemia Patients
|
Sheth, Samip
|
|
2019
|
13 |
3 |
p. e37-e38
|
artikel
|
| 17 |
Clinical management, psychosocial characteristics, and quality of life in patients with homozygous familial hypercholesterolemia undergoing LDL-apheresis in Turkey: Results of a nationwide survey (A-HIT1 registry)
|
Kayikcioglu, Meral
|
|
2019
|
13 |
3 |
p. 455-467
|
artikel
|
| 18 |
Cognitive Function in Patients on Evolocumab*
|
Ye, Qian
|
|
2019
|
13 |
3 |
p. e38-e39
|
artikel
|
| 19 |
Comparison of Atherosclerotic Plaque Characteristics among Normal and High Triglycerides (TGs) Patients
|
Cherukuri, Lavanya
|
|
2019
|
13 |
3 |
p. e22-e23
|
artikel
|
| 20 |
Comparison of EPA and DHA-Rich Fish Oils on NMR Lipoprotein Metabolism in Adults
|
Amar, Marcelo
|
|
2019
|
13 |
3 |
p. e47
|
artikel
|
| 21 |
Coronary Artery Calcium scores in asymptomatic minority subjects with phenotypic Familial Hypercholesterolemia*
|
Hester, Allison M.
|
|
2019
|
13 |
3 |
p. e16
|
artikel
|
| 22 |
Correlation between chylomicronemia diagnosis scores and post-heparin lipoprotein lipase activity
|
Khoury, Etienne
|
|
2019
|
13 |
3 |
p. e25-e26
|
artikel
|
| 23 |
18-Day Residential Lifestyle Program Improves Lipids
|
Ramirez, Francisco Eduardo
|
|
2019
|
13 |
3 |
p. e53
|
artikel
|
| 24 |
Determinants of response and tolerability of PCSK9 inhibitor therapy
|
Wierzbicki, Anthony S.
|
|
2019
|
13 |
3 |
p. e57-e58
|
artikel
|
| 25 |
Did the ACC/AHA/AACVPR/AAPA/ABC/ACPM/ADA/AGS/APhA/ASPC/NLA/PCNA cholesterol guidelines get apoB right?
|
Sniderman, Allan D.
|
|
2019
|
13 |
3 |
p. 360-366
|
artikel
|
| 26 |
Distinct phospholipid and sphingolipid species are linked to altered HDL function in apolipoprotein A-I deficiency
|
Zakiev, Emile
|
|
2019
|
13 |
3 |
p. 468-480.e8
|
artikel
|
| 27 |
Distribution of Apolipoprotein(a)-Containing Species in Human Plasma Assessed by Fast Protein Liquid Chromatography
|
Boffa, Michael
|
|
2019
|
13 |
3 |
p. e58
|
artikel
|
| 28 |
Editorial Board
|
|
|
2019
|
13 |
3 |
p. A1-A4
|
artikel
|
| 29 |
Effects (Critical Role) of Nitrite and Nitrate determinants in Saliva and Plasma Correlating Cardio Metabolic factors
|
Birudaraju, Divya
|
|
2019
|
13 |
3 |
p. e58-e59
|
artikel
|
| 30 |
Effects of Conjugated Linoleic Acid (CLA) on HDL-C and Triglyceride levels in Subjects with and without the Metabolic Syndrome: A Systematic Review and Meta-analysis
|
Moreno, Rossana Maria Calderon
|
|
2019
|
13 |
3 |
p. e45-e46
|
artikel
|
| 31 |
Effects of Marine Omega-3 Fatty Acids on Cardiovascular Outcomes in Patients with Ischemic Heart Disease: A Meta-Analysis*
|
Rahman, Hammad Ur
|
|
2019
|
13 |
3 |
p. e52-e53
|
artikel
|
| 32 |
Efficacy and Safety of Triplet Therapy With Bempedoic Acid, Ezetimibe, and Atorvastatin in Patients with Hypercholesterolemia
|
MacDougall, Diane
|
|
2019
|
13 |
3 |
p. e55
|
artikel
|
| 33 |
Eicosapentaenoic Acid, Unlike Arachidonic Acid, Maintains Normal Membrane Structure and Cholesterol Distribution Under Conditions of Hyperglycemia
|
Sherratt, Samuel
|
|
2019
|
13 |
3 |
p. e47-e48
|
artikel
|
| 34 |
Elevated apolipoprotein B as a risk-enhancing factor in 2018 cholesterol guidelines
|
Grundy, Scott M.
|
|
2019
|
13 |
3 |
p. 356-359
|
artikel
|
| 35 |
Enhanced Prediction of the Population at Risk of Atherothrombotic Disease†
|
Feeman Jr, W.E.
|
|
2019
|
13 |
3 |
p. e9-e10
|
artikel
|
| 36 |
Establishing reference parameters for total and active PCSK9 levels: A pilot study
|
Allen, Diane
|
|
2019
|
13 |
3 |
p. e1-e2
|
artikel
|
| 37 |
Evaluating a population health approach to statin use: pharmacist driven interventions in patients with type 2 diabetes mellitus*
|
Troksa, Kyle A.
|
|
2019
|
13 |
3 |
p. e31-e32
|
artikel
|
| 38 |
Evaluation of the Safety Profile of Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors in Patients with Chronic Kidney Disease*
|
Hernandez, Nubriel
|
|
2019
|
13 |
3 |
p. e41
|
artikel
|
| 39 |
Evolocumab in Patients With Type 2 Diabetes and Dyslipidemia on Background Statin: Primary Results of the China Population from the BERSON Clinical Trial
|
Chen, Yundai
|
|
2019
|
13 |
3 |
p. e6-e7
|
artikel
|
| 40 |
Exome Secondary Findings identifies an incidental FH prevalence rate of 1 in 500
|
Castro, Andrew
|
|
2019
|
13 |
3 |
p. e19-e20
|
artikel
|
| 41 |
Extremely low levels of low-density lipoprotein potentially suggestive of familial hypobetalipoproteinemia: A separate phenotype of NAFLD?
|
Mouzaki, Marialena
|
|
2019
|
13 |
3 |
p. 425-431
|
artikel
|
| 42 |
Familial Chylomicronemia Syndrome: Distinguishing the Rare Among the Common in Adults for Appropriate Management†
|
Ueda, Masako
|
|
2019
|
13 |
3 |
p. e35-e36
|
artikel
|
| 43 |
Familial Chylomicronemia Syndrome is associated with increased dietary fatty acid spillover in the circulation despite lower total postprandial triglycerides
|
Carpentier, Andre C.
|
|
2019
|
13 |
3 |
p. e25
|
artikel
|
| 44 |
Familial Hypercholesterolemia GENEtic evaluation of Minority patients with an LDL-C >190mg/dL: FH GENE-Minority Study
|
Cheeley, Mary Katherine
|
|
2019
|
13 |
3 |
p. e15-e16
|
artikel
|
| 45 |
Final Report of the OSLER-1 Study: Long-Term Evolocumab for the Treatment of Hypercholesterolemia
|
Koren, Michael
|
|
2019
|
13 |
3 |
p. e53-e54
|
artikel
|
| 46 |
For Whom The Lobe Folded.....When?
|
Lichtenberg, Robert Charles
|
|
2019
|
13 |
3 |
p. e28
|
artikel
|
| 47 |
Free glycerol correlate with post-heparin lipoprotein lipase activity and contribute to differentiate familial vs. multifactorial chylomicronemia
|
Brisson, Diane
|
|
2019
|
13 |
3 |
p. e26
|
artikel
|
| 48 |
From the editor: Atherosclerosis in different flavors
|
Guyton, John R.
|
|
2019
|
13 |
3 |
p. 341-342
|
artikel
|
| 49 |
Gender Differences in Response to PCSK9 Inhibitor Therapy
|
Ziajka, Paul
|
|
2019
|
13 |
3 |
p. e42
|
artikel
|
| 50 |
Genetic Testing for Hypertriglyceridemia - Pilot Data from a Single Center Lipid Clinic
|
Hadley, Trevor Dalton
|
|
2019
|
13 |
3 |
p. e17-e18
|
artikel
|
| 51 |
Geographic Variation In LDL-C Levels And Lipid Lowering Therapy Use In Patients With Atherosclerotic Cardiovascular Disease
|
Baum, Seth J.
|
|
2019
|
13 |
3 |
p. e32-e33
|
artikel
|
| 52 |
Glycosylated sphingolipids and progression to kidney dysfunction in type 1 diabetes
|
Lopes-Virella, Maria F.
|
|
2019
|
13 |
3 |
p. 481-491.e1
|
artikel
|
| 53 |
Guidelines impact cholesterol management
|
Yu, Stephanie
|
|
2019
|
13 |
3 |
p. 432-442
|
artikel
|
| 54 |
High Lp(a) associated with very premature coronary heart disease
|
Mobarek, Dalia
|
|
2019
|
13 |
3 |
p. 402-404
|
artikel
|
| 55 |
Homozygous Familial Hypercholesterolemia in the United States: Data from the CASCADE-FH Registry†
|
Cuchel, Marina
|
|
2019
|
13 |
3 |
p. e39
|
artikel
|
| 56 |
How Can We Reduce Cardiovascular Disease Risks in Black Women?
|
Thobani, Aneesha
|
|
2019
|
13 |
3 |
p. e40-e41
|
artikel
|
| 57 |
Hypertension and Tuberous Xanthomas predict Cardiovascular Disease in Familial Dysbetalipoproteinemia
|
Baass, Alexis
|
|
2019
|
13 |
3 |
p. e11
|
artikel
|
| 58 |
Identifying patient perceptions and attitudes regarding statin-associated diabetes mellitus
|
Gibson, Cheryl A.
|
|
2019
|
13 |
3 |
p. e7-e8
|
artikel
|
| 59 |
Impact of Monogenic Familial Hypercholesterolemia and Polygenic Hypercholesterolemia Cardiovascular Disease Risk*
|
Brunham, Liam R.
|
|
2019
|
13 |
3 |
p. e14
|
artikel
|
| 60 |
Implementation of cholesterol screening at 2 years of age
|
Hamilton, Luke
|
|
2019
|
13 |
3 |
p. e3-e4
|
artikel
|
| 61 |
Importance of Nutritional Intervention for Infants with Abetalipoproteinemia
|
Ueda, Masako
|
|
2019
|
13 |
3 |
p. e44
|
artikel
|
| 62 |
Incorporation of Genetic Testing for Familial Hypercholesterolemia Nearly Doubles Diagnosis Rate˄
|
Brown, Emily
|
|
2019
|
13 |
3 |
p. e14-e15
|
artikel
|
| 63 |
Increasing Diagnostic Yield for Inherited Lipidemias: Next-Generation Sequencing of An Expanded Panel
|
Kellogg, Gregory
|
|
2019
|
13 |
3 |
p. e16-e17
|
artikel
|
| 64 |
Intensity and Timing of Statin Initiation in Patients with initial LDL Greater Than 190 mg/dL in an Urban Medical Center: A Retrospective Observational Single Center University Experience*
|
Gokhale, Sanket R.
|
|
2019
|
13 |
3 |
p. e37
|
artikel
|
| 65 |
JCL roundtable. The 2018 AHA/ACC/Multisociety Cholesterol Guidelines: Process and product
|
Braun, Lynne T.
|
|
2019
|
13 |
3 |
p. 345-355
|
artikel
|
| 66 |
LDL-C Values and Lipid Lowering Therapy Utilization in a Medicare Fee For Service (FFS) Population
|
Desai, Nihar
|
|
2019
|
13 |
3 |
p. e11-e12
|
artikel
|
| 67 |
Lifestyle intervention improve the weight and exercise patterns of geriatric depressed patients
|
Ramirez, Francisco Eduardo
|
|
2019
|
13 |
3 |
p. e46
|
artikel
|
| 68 |
Lipase Maturation Factor 1 Contributes to ER Redox Homeostasis†
|
Neher, Saskia
|
|
2019
|
13 |
3 |
p. e26-e27
|
artikel
|
| 69 |
Lipid Effects of Dietary Education as a Function of Age and Gender
|
Friedrich, Debra Ann
|
|
2019
|
13 |
3 |
p. e46
|
artikel
|
| 70 |
Lipid Lowering With Bempedoic Acid Added to Proprotein Convertase Subtilisin/Kexin Type 9 Inhibitor Therapy: A Randomized Controlled Trial
|
McKenney, James
|
|
2019
|
13 |
3 |
p. e55-e56
|
artikel
|
| 71 |
Lipoprotein (a) testing in youth
|
Hamilton, Luke
|
|
2019
|
13 |
3 |
p. e4-e5
|
artikel
|
| 72 |
Low LDL cholesterol—Friend or foe?
|
Hartz, Jacob
|
|
2019
|
13 |
3 |
p. 367-373
|
artikel
|
| 73 |
Management of Dyslipidemia in Patients with Dermatomyositis: A Case Series
|
Bartsch, Kelly
|
|
2019
|
13 |
3 |
p. e41-e42
|
artikel
|
| 74 |
Marked reduction of Lipoprotein (a) with PCSK9 Inhibition in a statin intolerant patient: An Illustrative Case Report
|
Bramlet, Dean A.
|
|
2019
|
13 |
3 |
p. e5
|
artikel
|
| 75 |
Meta-analysis of Effects of Triglyceride Modifiers on Cardiovascular Outcomes*
|
Rahman, Hammad
|
|
2019
|
13 |
3 |
p. e23-e24
|
artikel
|
| 76 |
News from the NLA
|
|
|
2019
|
13 |
3 |
p. 343-344
|
artikel
|
| 77 |
Nontraditional Lipoprotein Biomarkers: Predictive Power and Risk Stratification*
|
Michael, Mary
|
|
2019
|
13 |
3 |
p. e2-e3
|
artikel
|
| 78 |
Patient Characteristics and Prescribing Patterns for Patients Approved and Denied PCSK9 Inhibitors in Real-World Practice
|
Smith, Alexander Blake
|
|
2019
|
13 |
3 |
p. e38
|
artikel
|
| 79 |
PCSK9 inhibition in patients with and without prior myocardial infarction or ischemic stroke: A pooled analysis of nine randomized-controlled studies of alirocumab
|
Bruckert, Eric
|
|
2019
|
13 |
3 |
p. 443-454
|
artikel
|
| 80 |
Perceived Barriers to Lipid Management for Suspected Familial Hypercholesterolemia Franco-American Founder Populations*
|
Mszar, Reed
|
|
2019
|
13 |
3 |
p. e34-e35
|
artikel
|
| 81 |
Perceived fatigue may be an overlooked barrier to successful therapeutic lifestyle change
|
Jarvis IV, Todd
|
|
2019
|
13 |
3 |
p. e9
|
artikel
|
| 82 |
Personalized Medicine for Dyslipidemias by RNA Interference-Mediated Reductions in Apolipoprotein C3 or Angiopoietin-Like Protein 3
|
Wong, So C.
|
|
2019
|
13 |
3 |
p. e15
|
artikel
|
| 83 |
Predicting Cardiovascular Disease in Familial Hypercholesterolemia: Risk Factors Counting
|
Baass, Alexis
|
|
2019
|
13 |
3 |
p. e11
|
artikel
|
| 84 |
Prescription of the proprotein convertase subtilisin/kexin type 9 inhibitor through the view of cholesterol guidelines
|
Sheth, Samip
|
|
2019
|
13 |
3 |
p. e33-e34
|
artikel
|
| 85 |
Prevalence of Diabetes Mellitus with REDUCE-IT-Like Indications: Ramifications for Residual Risk and Potential Risk Reduction
|
Nelson, John R.
|
|
2019
|
13 |
3 |
p. e46-e47
|
artikel
|
| 86 |
Prevalence of heterozygous familial hypercholesterolemia and combined hyperlipidemia phenotype in very young survivors of myocardial infarction and their association with the severity of atheromatous burden
|
Rallidis, Loukianos S.
|
|
2019
|
13 |
3 |
p. 502-508
|
artikel
|
| 87 |
Prevalence of Pathogenic Variants of Lipoprotein Metabolism Genes in a Single Lipidology Clinic*
|
Benes, Lane B.
|
|
2019
|
13 |
3 |
p. e13-e14
|
artikel
|
| 88 |
Prevalence of US Adults With Triglycerides ≥135 mg/dL: NHANES 2007-2014
|
Philip, Sephy
|
|
2019
|
13 |
3 |
p. e22
|
artikel
|
| 89 |
Race/Ethnic differences in dyslipidemia patterns in Youth
|
Bansal, Nidhi
|
|
2019
|
13 |
3 |
p. e43
|
artikel
|
| 90 |
Real-world health care costs incurred by early adopters of PCSK9 inhibitor therapy*
|
Milks, Michael Wesley
|
|
2019
|
13 |
3 |
p. e56-e57
|
artikel
|
| 91 |
Relationship between Lipid Levels and Coronary Atherosclerotic Plaque Scores by Coronary Computed Tomography Angiography (CTA) in Subjects with Elevated Triglycerides
|
Lee, Alice
|
|
2019
|
13 |
3 |
p. e27
|
artikel
|
| 92 |
Serving the Underserved: Are We Overlooking HoFH Patients?
|
Hemphill, Linda C.
|
|
2019
|
13 |
3 |
p. e51-e52
|
artikel
|
| 93 |
Severe Combined Hyperlipidemia, Heterozygous APOE p.V254E, Pancreatitis, Diabetes Mellitus, and Plantar Xanthomas*
|
Cheung, Brian
|
|
2019
|
13 |
3 |
p. e24-e25
|
artikel
|
| 94 |
Severe hypercholesterolemia in a 2-year-old
|
Horner, Susanna
|
|
2019
|
13 |
3 |
p. 393-396
|
artikel
|
| 95 |
Severe hypercholesterolemia secondary to drug-induced cholestatic liver injury
|
Venci, Diana Vinh
|
|
2019
|
13 |
3 |
p. e34
|
artikel
|
| 96 |
Significance of Lipid Management in Cardiac Transplant Population
|
Poornima, Indu
|
|
2019
|
13 |
3 |
p. e42-e43
|
artikel
|
| 97 |
Table of Contents
|
|
|
2019
|
13 |
3 |
p. A5-A7
|
artikel
|
| 98 |
Technological advancements in CME increase knowledge gains and the translation of education to practice within cardiovascular care.
|
Frese, Matthew
|
|
2019
|
13 |
3 |
p. e33
|
artikel
|
| 99 |
The Economic Burden of Hypertriglyceridemia Among US Adults With Diabetes or Atherosclerotic Cardiovascular Disease on Statin Therapy*
|
Case, Brian C.
|
|
2019
|
13 |
3 |
p. e20-e22
|
artikel
|
| 100 |
The Impact of Lipoprotein(a) Levels on Cardiovascular Risk and Statin Recommendation*
|
Yoo, Bianca Wheyoung
|
|
2019
|
13 |
3 |
p. e3
|
artikel
|
| 101 |
The Role of Niacin in the Management of Dyslipidemia†
|
Keenan, Joseph M.
|
|
2019
|
13 |
3 |
p. e29-e30
|
artikel
|
| 102 |
The Role of the Novel Lipokine Palmitoleic Acid in Cardiovascular Health: from Bench to Bedside*
|
Yang, Zhi-Hong
|
|
2019
|
13 |
3 |
p. e45
|
artikel
|
| 103 |
The STatin Adverse Treatment Experience Survey: Experience of patients reporting side effects of statin therapy
|
Jacobson, Terry A.
|
|
2019
|
13 |
3 |
p. 415-424
|
artikel
|
| 104 |
Trends and goal achievement in LDL cholesterol according to cardiovascular risk in Chile: Overview from 2003 to 2016-2017 National Health Surveys
|
Echeverria, Guadalupe
|
|
2019
|
13 |
3 |
p. e13
|
artikel
|
| 105 |
Uncovering barriers and facilitators to caring for familial hypercholesterolemia*
|
Jones, Laney K.
|
|
2019
|
13 |
3 |
p. e30
|
artikel
|
| 106 |
Update on dyslipidemia patterns in Chilean adult population: Findings from the 2016-2017 National Health Survey
|
Mendoza, Paulina
|
|
2019
|
13 |
3 |
p. e51
|
artikel
|
| 107 |
Use of Lipoprotein(a) in clinical practice: A biomarker whose time has come. A scientific statement from the National Lipid Association
|
Wilson, Don P.
|
|
2019
|
13 |
3 |
p. 374-392
|
artikel
|
| 108 |
Virtual Patient Simulation Improves Clinical Decision-Making in Dyslipidemia: Success of Online CME
|
Spyropoulos, Jelena
|
|
2019
|
13 |
3 |
p. e52
|
artikel
|
Tijdschrift beschrijving